Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215624 · ClinicalTrials.gov registry record
Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study
A clinical trial of Malignant Female Reproductive System Neoplasm and Malignant Digestive System Neoplasm, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT07215624: Recruiting study of Malignant Female Reproductive System Neoplasm and Malignant Digestive System Neoplasm, sponsored by Wake Forest University Health Sciences.
NCT07215624 is a study of Malignant Female Reproductive System Neoplasm and Malignant Digestive System Neoplasm that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 500 participants, above the 377-participant average among 18 other Malignant Female Reproductive System Neoplasm trials with a reported enrollment target (33% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07215624, a study of Malignant Female Reproductive System Neoplasm and Malignant Digestive System Neoplasm, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the use of extended venous thromboembolism prophylaxis (ePPx) following abdominopelvic cancer surgery within the NCI Community Oncology Research Program (NCORP) network, targeting surgeons and surgical advanced practice providers (APPs).
Primary Outcome
Will apply only to surgeons completing the Part 1 survey. Will be defined as answering "Yes, all cases or almost all cases" on the survey question asking about prescription of ePPx after discharge. The proportion of surgeons self-reporting utilization of guideline concordant ePPx will be estimated and reported along with an exact 95% confidence interval.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (20)
Iowa
- Mercy Hospital - Cedar Rapids
- Oncology Associates at Mercy Medical Center - Cedar Rapids
- Blank Children's Hospital - Des Moines
- Mercy Medical Center - Des Moines - Des Moines
- Iowa Lutheran Hospital - Des Moines
Delaware
- Helen F Graham Cancer Center - Newark
- Medical Oncology Hematology Consultants PA - Newark
- Christiana Care Health System-Christiana Hospital - Newark
Georgia
- Northside Hospital - Atlanta
- Augusta University Medical Center - Augusta
- Northside Hospital - Gwinnett - Lawrenceville
Michigan
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor - Ann Arbor
- Chelsea Hospital - Chelsea
- Trinity Health Saint Mary Mercy Livonia Hospital - Livonia
Minnesota
- Sanford Joe Lueken Cancer Center - Bemidji
- Essentia Health Saint Joseph's Medical Center - Brainerd
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
Illinois
- Carle Cancer Center - Urbana
Maine
- MaineHealth Maine Medical Center- Scarborough - Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2027-06-01 |
What NCT07215624 shows while recruiting
NCT07215624 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 377-participant average among 18 other Malignant Female Reproductive System Neoplasm trials with a reported enrollment target (33% higher).
The record links to 3 conditions, with Malignant Female Reproductive System Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT07215624 names 20 study sites across 9 states, led by Iowa, Delaware, Georgia.
Frequently Asked Questions
What is clinical trial NCT07215624 about?
NCT07215624 is a clinical study titled "Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study". This study evaluates the use of extended venous thromboembolism prophylaxis (ePPx) following abdominopelvic cancer surgery within the NCI Community Oncology Research Program (NCORP) network, targeting surgeons and surgical advanced practice providers (APPs).
What is the current status of trial NCT07215624?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2026-01-15. Estimated completion is 2027-06-01.
What conditions does trial NCT07215624 study?
This clinical trial studies the following conditions: Malignant Female Reproductive System Neoplasm, Malignant Digestive System Neoplasm, Malignant Genitourinary System Neoplasm.
What interventions are being tested in trial NCT07215624?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT07215624?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215624 being conducted?
This trial has 20 study locations across Arkansas, Delaware, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Female Reproductive System Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07215624's enrollment target sits among peer trials
500 3rd of 18 higher than 15 of 18 other Malignant Female Reproductive System Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Female Reproductive System Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Individualized Online Home-Based Exercise Program for Improving Symptoms in Gynecologic Cancer Survivors
RECRUITING · NA
-
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery
RECRUITING
-
Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal or Gynecological Cancer
RECRUITING · Phase 2
-
REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss
RECRUITING · Phase 3
-
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
RECRUITING · Phase 2
-
Cancer Genetic Testing in Ethnic Populations
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI